Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008896 | 0.91 | TP53 (0.38) | TP53RORCEPHX2KDM4EALDH1A1 | |
| SCHEMBL1843046 | 0.83 | SCN9A (0.40) | MAPTNAMPT | |
| SCHEMBL1840774 | 0.81 | ROCK2 (0.45) | TP53KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2009522 | 0.81 | ROCK2 (0.45) | TP53KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2009523 | 0.81 | ROCK2 (0.45) | TP53KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1842002 | 0.80 | BRPF1 (0.41) | RORCHPGDS | |
| SCHEMBL1840778 | 0.80 | BRPF1 (0.41) | RORCHPGDS | |
| SCHEMBL1840633 | 0.74 | HPGD (0.41) | TP53RORCEPHX2KDM4EALDH1A1 | |
| SCHEMBL1840121 | 0.73 | BRPF1 (0.43) | — | |
| SCHEMBL1839208 | 0.73 | BRPF1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | TP53 3844/4885RORC 862/4885EPHX2 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.